bioAffinity Technologies Appoints Three New Medical and Scientific Advisory Board Members

bioAffinity Technologies Inc. has announced new appointments to its Medical and Scientific Advisory Board, welcoming to the governing body David Ost, M.D., University of Texas MD Anderson Cancer Center; Daniel Sterman, M.D., New York University Langone Medical Center; and J. Scott Ferguson, M.D., University of Wisconsin School of Medicine and Public Health.

The appointments reflect a planned board expansion to ensure alignment with bioAffinity’s current clinical, scientific, and commercial priorities, including the ongoing integration of CyPath Lung, a noninvasive diagnostic test for lung cancer, into the standard of care for indeterminate pulmonary nodules.

Drs. Ost, Sterman, and Ferguson join current board members David Hill, M.D., chair of the American Lung Association Board of Directors; Neil Alexis, Ph.D., principal investigator at the University of North Carolina School of Medicine Center for Environmental Medicine, Asthma and Lung Biology; Sheila Habib, M.D., director of the Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at South Texas Veterans Health Care Systems, Audie L. Murphy Memorial Veterans Hospital; and Sandeep Bansal, M.D., medical director of Lung Innovations Network.

“Our Medical and Scientific Advisory Board’s experience in real-world pulmonary practice and lung health supports our corporate and clinical mission to improve outcomes for patients by detecting lung cancer at the earliest stages when it is most treatable and survivable,” bioAffinity Technologies Chief Medical Officer Gordon Downie, M.D., Ph.D., stated. “Lung cancer is still the leading cause of cancer-related deaths, and our focus remains on patient care and how our CyPath Lung diagnostic test can best inform clinicians and change the course of lung cancer diagnosis and treatment.”

Dr. Ost, a leader in interventional pulmonology, thoracic oncology, and critical care, currently serves as professor of Medicine and chief of Pulmonary, Critical Care, and Sleep Medicine at MD Anderson Cancer Center. His work focuses on improving lung cancer diagnosis, staging, and treatment.

Dr. Sterman, professor of Medicine and chief of the Division of Pulmonary, Critical Care, and Sleep Medicine at NYU Langone Health, is recognized for his pioneering work in interventional pulmonology. His research focuses on using gene therapy and immunotherapy to treat lung cancer and mesothelioma and to improve and prolong patients’ quality of life.

Dr. Ferguson, professor of Medicine and director of Interventional Pulmonology at the University of Wisconsin School of Medicine and Public Health, specializes in treating complex lung conditions. He is recognized for his advanced diagnostic techniques for lung cancer, thoracic oncology, and therapeutic bronchoscopy.

“These appointments strengthen our panel of clinical and scientific leaders helping to guide our work as we continue to advance CyPath Lung as a vital diagnostic tool to detect lung cancer at an early stage in high-risk patients,” bioAffinity Technologies President/CEO Maria Zannes said. “Drs. Ost, Sterman, and Ferguson are nationally recognized leaders in pulmonary medicine and lung cancer care. Their advice and counsel will be instrumental as we focus on clinical implementation and broader adoption of our diagnostic platform.”

CyPath Lung is a noninvasive test designed to improve early lung cancer detection in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patients’ sputum that indicate malignancy. CyPath Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.

bioAffinity Technologies Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity, and accuracy for detecting early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.